Danaher Corporation Rarely Cheap, But A Proven Winner

Danaher is no bargain, but the turnaround in the diagnostics business has been impressive.

Feb 11, 2014 at 9:37AM

If you're looking for a well-run conglomerate trading at a significant discount to fair value, you're probably going to pass over Danaher (NYSE:DHR). That's typically the case, though, as this company's demonstrated strength in generating margins, cash flow, and returns on capital makes it a perennial favorite with institutional investors.

Even if the expected returns from the stock don't meet your hurdle rate today, Danaher looks like a good name for a watch list. Management has over $8 billion in dry powder for M&A activity and a clear desire to do a large deal (or two). Combine that with a turned-around diagnostics business and underappreciated growth opportunities in product ID and water treatment, and this is a company with solid long-term prospects.

Growth seems to be picking up a bit
When Danaher reported earnings in January, the company delivered 3.5% "core" revenue growth, a slight acceleration from the 3% growth seen in the third quarter. All of the major reporting segments were up, with test & measurement providing its best performance in quite some time. Life sciences & diagnostics also continues to perform well, with strong sale performance in clinical automation and the Chinese diagnostics business.

Danaher saw a slight pick up in gross margin and managed to leverage the 6% reported revenue increase into a slightly greater than 6% operating income improvement, excluding a $31 million pre-tax impairment charge. Test and measurement did well on that revenue growth (with segment income up 11%), and the LS&D business was a major contributor to earnings growth as operating income rose more than 23% on a 2.5% improvement in operating margin.

Diagnostics is healthy again
Danaher has done an excellent job of turning around Beckman Coulter, and this division's operating margins are now basically in line with the norms of the industry. Now the question is more about where the company wants to take this business in the future.

Amidst Roche, Abbott (NYSE:ABT), and Siemens, Danaher is one of the largest players in immunoassay, a $4 billion-plus/year segment of diagnostics. Danaher is also quite strong in clinical chemistry, where it competes with a similar roster of rivals. One of the key factors here is the ongoing automation of the diagnostics space. Roche is quite strong in automation, but Abbott and Siemens have been lagging – giving Danaher a real opportunity to gain share (particularly in clinical chemistry). If Abbott does not improve its automation efforts, there is a real chance for Danaher to grab share in the large lab market, and Siemens' commitment to this space has been questioned as management continues a seemingly endless review of the businesses in which it wants to compete for the long term.

Molecular diagnostics is a different story, though. Roche has an exceptionally strong presence in this market, and Abbott has a credible footprint, while Danaher does not. As this is a large market (over $3 billion today) and one of the fastest-growing segments of diagnostics, this could be a focus for future growth, whether internally driven or through M&A.

Several internal growth opportunities
Danaher is a highly acquisitive company, and that is not likely to change. While the prospects for a large deal are tantalizing, I wouldn't sleep on the company's prospects for internally driven growth as well.

Ballast water treatment could be a multibillion dollar opportunity for the company's Environmental segment. Likewise, the product ID space is a multibillion dollar market where Danaher already appears to have about 20% share, even as it competes with Dover in the printing sub-market. Given the opportunities to strengthen its hand in hardware and software, I would not be surprised if this were an area of focus for M&A, but there is ample room for internal growth as well.

The bottom line
I expect Danaher to post mid-single digit revenue and FCF growth over the long term, with M&A likely to continue to factor as a major part of the company's strategy. That leads to a DCF-based fair value of around $71 today. Although that is below the current stock price, I calculate my discount rates on a required return basis, so the worst I can say about Danaher is that it is not so likely to beat the market year in and year out at today's price. Were the stock to pull back into the $60's, I would seriously consider adding shares with the intention of holding for many years.

Danaher may have serious trouble catching up with this stock in 2014...
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers